North Dakota State Investment Board Sells 6,420 Shares of Incyte Corporation $INCY

North Dakota State Investment Board decreased its position in Incyte Corporation (NASDAQ:INCY) by 38.5% in the third quarter, according to its most recent Form 13F filing with the SEC. The firm owned 10,258 shares of the biopharmaceutical company’s stock after selling 6,420 shares during the period. North Dakota State Investment Board’s holdings in Incyte were worth $1,245,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors also recently bought and sold shares of INCY. Trails Edge Capital Partners LP bought a new stake in Incyte during the 2nd quarter valued at $17,570,800. Twin Capital Management Inc. purchased a new stake in shares of Incyte in the 1st quarter worth $875,000. BlackRock Inc. purchased a new stake in shares of Incyte in the 2nd quarter worth $2,044,189,000. Tidal Investments LLC lifted its holdings in shares of Incyte by 33.4% in the 2nd quarter. Tidal Investments LLC now owns 102,834 shares of the biopharmaceutical company’s stock worth $11,657,000 after buying an additional 25,768 shares during the period. Finally, Mediolanum International Funds Ltd grew its position in shares of Incyte by 25.4% during the 1st quarter. Mediolanum International Funds Ltd now owns 60,300 shares of the biopharmaceutical company’s stock worth $5,447,000 after buying an additional 12,227 shares in the last quarter. Institutional investors own 96.97% of the company’s stock.

More Incyte News

Here are the key news stories impacting Incyte this week:

• Positive Sentiment: Incyte reported third-quarter revenue of $1.56 billion, up 14% year over year and above the $1.46 billion analyst estimate. Adjusted loss of $3.60 per share was narrower than expected, helping support the stock. INCY Q3 Loss Narrower Than Expected, Sales Beat, FY’26 View Raised
• Positive Sentiment: The company raised 2026 total net-sales guidance to $5.21 billion-$5.30 billion, from $5.13 billion-$5.26 billion previously. Opzelura guidance was also increased to $1.10 billion-$1.12 billion, reflecting continued demand. Incyte signals 2026 net sales outlook as Opzelura guidance rises
• Positive Sentiment: Product trends were favorable: Opzelura sales rose 36% to $255 million, while hematology and oncology portfolio sales increased 38% to $235 million. Jakafi and Jakafi XR sales grew 4% to $827 million. Incyte Reports $1.56 Billion Third-Quarter Revenue and Raises 2026 Sales Guidance
• Positive Sentiment: Barclays raised its price target from $139 to $143 and maintained an “overweight” rating, implying substantial upside and reinforcing the bullish reaction. Barclays Incyte analyst recommendation
• Neutral Sentiment: Wells Fargo lowered its target slightly to $127 and kept an “equal weight” rating, while RBC raised its target to $117 but retained a “sector perform” rating. The changes indicate limited conviction among some analysts. Wells Fargo Incyte analyst recommendation
• Negative Sentiment: Incyte posted a GAAP loss largely because of a $1.23 billion in-process research and development charge tied to the Vega Therapeutics acquisition. The unusual charge obscures underlying operating strength and may keep investors focused on acquisition execution. Incyte Posts Q3 Loss on Vega Acquisition Charge

Incyte Stock Performance

Shares of Incyte stock opened at $120.39 on Friday. The company has a market capitalization of $24.40 billion, a PE ratio of 55.09, a P/E/G ratio of 4.83 and a beta of 0.74. The company has a 50-day simple moving average of $120.49 and a two-hundred day simple moving average of $108.14. Incyte Corporation has a one year low of $89.25 and a one year high of $132.60.

Incyte (NASDAQ:INCY) last released its quarterly earnings results on Thursday, October 29th. The biopharmaceutical company reported ($3.60) EPS for the quarter, beating the consensus estimate of ($3.93) by $0.33. Incyte had a net margin of 6.71% and a return on equity of 7.92%. The business had revenue of $1.56 billion during the quarter, compared to analyst estimates of $1.46 billion. During the same period in the prior year, the firm posted $2.26 earnings per share. The company’s quarterly revenue was up 14.0% on a year-over-year basis. On average, equities analysts predict that Incyte Corporation will post 1.97 earnings per share for the current fiscal year.

Insider Activity at Incyte

In related news, insider Pablo Cagnoni sold 10,801 shares of the business’s stock in a transaction that occurred on Wednesday, August 19th. The shares were sold at an average price of $125.56, for a total transaction of $1,356,173.56. Following the completion of the transaction, the insider owned 183,200 shares in the company, valued at $23,002,592. The trade was a 5.57% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 16.20% of the stock is currently owned by company insiders.

Analyst Ratings Changes

INCY has been the topic of several research reports. Royal Bank Of Canada raised their price target on Incyte from $114.00 to $117.00 and gave the company a “sector perform” rating in a research note on Friday. Wells Fargo & Company lowered their price objective on shares of Incyte from $128.00 to $127.00 and set an “equal weight” rating for the company in a research note on Friday. Sanford C. Bernstein reaffirmed a “market perform” rating and issued a $104.00 price objective on shares of Incyte in a research note on Thursday, August 13th. JPMorgan Chase & Co. increased their target price on shares of Incyte from $120.00 to $123.00 and gave the stock a “neutral” rating in a report on Monday, September 28th. Finally, Cantor Fitzgerald reissued a “neutral” rating on shares of Incyte in a research report on Friday, September 11th. Twelve research analysts have rated the stock with a Buy rating, twelve have given a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, Incyte has a consensus rating of “Hold” and a consensus target price of $132.90.

About Incyte

Incyte Corporation is a biopharmaceutical company that discovers, develops and commercializes medicines for oncology and inflammatory or autoimmune diseases. The company focuses on therapies that target specific biological pathways, including Janus kinase (JAK), fibroblast growth factor receptor (FGFR) and other mechanisms involved in cancer and immune-related conditions.

Its key products include Jakafi (ruxolitinib), a JAK inhibitor used in the United States for certain blood cancers and graft-versus-host disease; Opzelura (ruxolitinib cream), a topical treatment for atopic dermatitis and nonsegmental vitiligo; and Pemazyre (pemigatinib), an FGFR inhibitor approved for selected patients with cholangiocarcinoma and certain myeloid or lymphoid neoplasms.